Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
In Medtronic’s case specifically, the EY authors write, the company reported that its ability to predict and modulate supply ...
On October 25, 2025, the United States Court of Appeals for the Ninth Circuit reaffirmed a fundamental protection under the National Labor ...
The best-performing organizations have decision-makers who focus on clarity, accountability and support when implementing ...
Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically ...
In this podcast, hear from inspiring women executives and founding members of Questrom’s Women in Business Alumnae Council as ...
Silver Beech Capital delivered 19.5% annualized returns since inception, navigating a market untethered from fundamentals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback